Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer Says
Ascentage Pharma Group (AAPG) is entering 2026 with growing commercial momentum in China and a pipel
| Ticker |
AAPG
|
| CIK | 0002023311 |
| SIC | 2834 |
| Sector | Manufacturing |
| Industry Category | Pharmaceutical Products |
| Industry Group | Pharmaceutical Preparations |
| Address | 68 XINQING ROAD, SUZHOU INDUSTRIAL PARK, SUZHOU , JIANGSU, China |
| Website | www.ascentage.com |
| Phone | 86 512 8555 7777 |
| CEO | Dajun Yang |
| Employees | 600 |
Our team will help you customize a package that meets the needs of your business.
Request a Consultation|
Standardized FinancialsdocsIntrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals. For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards. Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics: |
|||||||||||||||||||||
|
Income Statement
|
Balance Sheet
|
||||||||||||||||||||
|
Cash Flow Statement
|
Calculations
|
||||||||||||||||||||
|
Latest NewsdocsIntrinio provides up-to-date news articles on every US company from various sources. Here are several examples: |
Ascentage Pharma Builds Momentum With 2 'Potential Blockbuster' Drugs, Oppenheimer SaysAscentage Pharma Group (AAPG) is entering 2026 with growing commercial momentum in China and a pipel Ascentage Pharma Reports Full Year 2025 Unaudited Financial Results and Provides Business UpdatesProduct sales and commercial rights revenues in 2025 increased 90% year-over-year to US$82.1 million (RMB574.1 million)Sales of Olverembatinib increased 81% year-over-year to US$62.2 million (RMB435.3 million) Sales of Lisaftoclax since launch during last five months of 2025 were US$10.1 million (RMB 70.6 million)Nine registrational Phase III clinical trials are in progress worldwide, including four cleared by FDA and EMAChinese (Mandarin) investor event with simultaneous conference call and web Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026ROCKVILLE, Md. and SUZHOU, China, March 17, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial stage, integrated biopharmaceutical company engaged in the discovery, development and commercialization of novel, differentiated therapies to address unmet medical needs in cancer, announced that four abstracts highlighting the latest preclinical results from its pipeline programs have been selected for poster presentations at the American Ass Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026ROCKVILLE, Md. and SUZHOU, China, March 11, 2026 (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (Ascentage Pharma) (NASDAQ: AAPG; HKEX: 6855) (referred herein as “Ascentage Pharma,” the “Company,” “we,” “us” or “our”), a global, commercial stage, integrated biopharmaceutical company engaged in discovering, developing and commercializing novel, differentiated therapies to address unmet medical needs in cancer, today reported it will release its full year 2025 unaudited results and provi A Look At Ascentage Pharma Group International’s Valuation After Recent Share Price MovesWhat Recent Returns Say About Ascentage Pharma Group International Ascentage Pharma Group International (SEHK:6855) has drawn attention after a 4.0% gain over the past day, contrasting with negative moves over the past week, month and past 3 months. For investors tracking performance, the shares show a month return of about a 3.5% decline and a past 3 months return of about a 27.2% decline, while the 1 year total return stands at 16.5% and the 3 year total return is described as very... |